When Safety Depends on Coincidence: A Near-Miss in Radium-223 Therapy Revealing Latent Vulnerabilities in Theranostics Emergency Care

This article presents a near-miss event in which a patient with metastatic castration-resistant prostate cancer underwent emergency orthopedic surgery 21 days after Radium-223 administration. A safe outcome in this case depended on two coincidences: an incidental discovery of treatment history by a nurse and sufficient elapsed time for decay and clearance. Without the former, surgery would have proceeded without radiological assessment or appropriate precautions; without the latter, standard radiation safety precautions alone would have been insufficient to manage the hazard even with full radiological awareness. Through root cause analysis, we identified an information gap and an unrecognized dependence on favorable boundary conditions as the primary latent vulnerabilities. To quantify the unmanaged hazard, a deterministic hazard estimation demonstrated that surface contamination could have reached 386-fold above the US regulatory limit if the emergency had occurred 1 hour after administration. However, it fell sharply to approximately the regulatory limit at 24 hours due to physical decay and biological clearance. Crucially, even with minimal hemorrhage (30 mL), the contamination 1 hour after administration would still exceed the US statutory threshold 5.8-fold. These findings support a conceptual reframing: time functions as an intrinsic safety measure in radioisotope therapy by reducing the hazard itself through physical decay and biological clearance, independent of human compliance. Because compliance-driven administrative controls remain vulnerable during acute emergencies, institutions must explicitly operationalize time as an autonomous safety measure. To achieve this, we propose a three-tiered governance framework established at therapy initiation—that explicitly recognizes time as an intrinsic safety measure—assigning clear responsibilities to the prescribing physician as the primary clinical lead, the Radiation Safety Committee for operational protocols, and hospital executive management for infrastructure deployment.